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941In quantitative polymerase chain reaction analysis, the spike-in
control is used to adjust for differences in extraction efﬁciency
between samples (5), and the intersample deviation of Cel-miR-39
measurements is usually less than 1 cycle. However, immediately
after administration of the heparin bolus, the detectability of
Cel-miR-39 decreases by approximately 3 cycles. This effect is
conﬁned to the ﬁrst hours after heparin dosing and directly
related to the half-life of heparin in the circulation. Thus, heparin
could have interfered with the quantitation of miRNA after
transcoronary ablation of septal hypertrophy. The accompanying
editorial noted “the stunning precocity of elevation in the pe-
ripheral circulation of miR-1 and miR-133: only 15 min” (6). If
baseline blood samples were taken before administration of
heparin, then the rapid increase may at least in part be explained
by the effect of heparin on the normalization control. If the
baseline samples were taken after the heparin bolus, then the
reference samples are not suitable for measurements of miRNA
after the ﬁrst hour post-dose. Furthermore, a signiﬁcant increase
in plasma miR-21 levels was previously observed after thigh cuff–
induced ischemia/reperfusion injury (7). Plasma miR-21 levels are
also affected by antiplatelet medication (8). Thus, miR-21 may
not be a suitable control in this setting. Describing the nature
and timing of treatments administered in miRNA biomarker
studies is necessary to facilitate interpretation of data and prevent
confounding by treatment effects.*Manuel Mayr, MD, PhD
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595–600.ReplyEffects of Heparin on
Temporal MicroRNA ProﬁlesWe read with great interest the letter by Dr. Mayr and colleagues
regarding our work and the important topic of the effects of heparin
on temporal microRNA (miRNA) proﬁles and the best timing of
miRNA measurement after administration of heparin. Dr. Mayr
and colleagues were recently able to show that both the timing of
blood sampling relative to heparin dosing and the normalization
procedure are critical for reliable miRNA measurements in patients
receiving intravenous heparin (2,3). At this point, it can clearly be
stated that heparin is not the only confounder in the setting of
miRNA measurements; several factors, including different isolation
protocols, blood sample type (plasma or serum), and inﬂammation-
driven shifts in hematopoietic compartments after myocardial
infarction, appear to further affect the detection of cell-free (truly
circulating) miRNA (4).
With reference to the letter, the baseline blood samples in our
study (1) were taken before administration of heparin. Therefore,
we have a true control for the comparison of miRNA concen-
trations after transcoronary ablation of septal hypertrophy. The
transcoronary ablation of septal hypertrophy procedure itself was
performed after administration of heparin (bolus 5,000 IU hep-
arin). The miRNAs were isolated from serum samples before
miRNA isolation and spiking with native cel-miR-39. The
samples were treated with heparinase to minimize the inﬂuence
of heparin on the miRNA measurements. Of course, we cannot
entirely exclude the further existence of an effect of heparin, but
pre-study tests using the heparinase protocol showed comparable
results for miRNA concentrations with and without heparin.
Furthermore, our results clearly show a steep increase in miR-1
and miR-133a levels (approximately a 30-fold change) within
60 min after induction of myocardial infarction. Even if heparin
were to cause a 30% difference in miRNA concentrations, the
difference compared with miRNA concentrations at 15 min
would still be signiﬁcant.
The patients in our study were without antiplatelet medication.
Therefore, we can exclude the interference of this medication with
the measurement of miR-21 concentrations. Nevertheless, miR-
21 is known to be up-regulated in the presence of cardiac hy-
pertrophy. Thus, an inﬂuence on this subset cannot be entirely
excluded.
Although methodological issues may slightly interfere with the
ﬁnal miRNA measurements, our results add important information
to this new ﬁeld, and miRNAs may well have a future as bio-
markers for myocardial ischemia.*Christoph Liebetrau, MD
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Randomization Analyses
in Selection of Secretory
Phospholipase A2-IIA as a
Valid Therapeutic Target for
Prevention of Cardiovascular
Disease
Holmes et al. (1) investigated the association between secretory
phospholipase A2-IIA (sPLA2-IIA) as a potential therapeutic
target for prevention of cardiovascular disease, using observational
studies between the PLA2G2A rs11573156 variant and cardiovas-
cular events, and deductions from published data with the pan-
sPLA2 inhibitor varespladib methyl. The validity of the analysis by
Holmes et al. remains unclear due to inaccurate summary of data,
incorrect assumptions related to the biology of sPLA2-IIA, and the
pharmacological effects of varespladib (2). For brevity, the major
issues include the following:
1. No reporting of the absolute values for sPLA2-IIA levels and
activity, which is important because of variable results with
different analytical methods and marked differences in
sPLA2 levels that result from the acute phase reaction in
patients with acute coronary syndrome versus patients with
stable coronary heart disease;
2. Use of total sPLA2 activity as a surrogate for sPLA2-IIA
activity;
3. Investigation of the PLA2G2A rs11573156 variant with
messenger RNA expression even though none of the variants
illustrated in Figure 2 included the variant as a genetic tool
in the current analysis;
4. A marginally signiﬁcant correlation between PLA2G2A
rs11573156 variant and sPLA2 activity despite highercorrelations between sPLA2-IIA mass and sPLA2 activity
reported in Online Figure 2;
5. Reporting of percentage changes in sPLA2 levels and sPLA2
activity when absolute changes may be more important,
particularly because of wide differences in baseline sPLA2-
IIA levels in different cohorts;
6. A lack of clear presentation from the original studies of the
reported effects of varespladib on sPLA2-IIA mass, and in
fact, the table understates the effect of varespladib 500 mg/
day on sPLA2-IIA mass by more than 50%, whereas the
reduction is 80%; the authors concluded incorrectly that the
homozygous rs11573156C allele resulted in a reduction in
sPLA2-IIA mass “similar” to the effect of varespladib;
7. Biomarker effects of sPLA2 in randomized clinical trials
with >500 subjects should have included only the FRANCIS
(Fewer Recurrent Acute Coronary Events With Near-Term
Cardiovascular Inﬂammation Suppression)-ACS trial on the
basis of the sample size requirement, but 3 trials are reported;
8. Biomarker effects should have been reported from the
PLASMA I (Phospholipase Levels And Serological
Markers of Atherosclerosis) and PLASMA II (Phospholi-
pase Levels And Serological Markers of Atherosclerosis II)
trials because these trials reported results from clinically
stable patients, whereas the FRANCIS-ACS trial mandated
a change in statin therapy for all patients to atorvastatin 80
mg daily regardless of their prior statin regimen;
9. Varespladib is a pan-sPLA2 inhibitor with similar efﬁcacy in
lowering groups IIA and X sPLA2 with somehow lower
potency against group V, despite the incorrect data cited in
this report (3).
Moreover, the use of Mendelian randomization studies to deduce
pharmacological effects does not account for the properties of the
speciﬁc inhibitor. Speciﬁcally, varespladib is hydrophilic and may
not penetrate into vascular tissues with sufﬁcient potency to reduce
intracellular effects versus the consistent effects on plasma bio-
markers. Also, because varespladib methyl inhibits sPLA2-X and a
recent report by Ait-Oufella et al. (4) demonstrated that over-
expression of sPLA2-X is atheroprotective, nonspeciﬁc effects of
varespladib as a pan inhibitor may have positive and negative effects.
In addition, preliminary results from theVISTA-16 trial (Evaluation
of Safety and Efﬁcacy of Short-term A-002 Treatment in Subjects
With Acute Coronary Syndrome) indicate an increase in myocardial
infarctions, so the effect of varespladib was harmful (5). As discussed
previously, proinﬂammatory pathways are redundant, and multiple
anti-inﬂammatory pathways modulate inﬂammatory responses.
In conclusion, careful review of primary data and cautious con-
clusions must be considered in these pharmacogenetic analyses (6).*Robert S. Rosenson, MD
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